Dr. Parker on current role of FDA-approved PSMA-PET imaging agents in clinical practice

Currently there are 2 FDA-approved, commercially available PSMA-PET imaging agents, which are Gallium 68 PSMA-11 (Ga 68 PSMA-11) and piflufolastat F 18 (Pylarify). In this video, William P. Parker, MD, discusses their approved indications and current role in the prostate cancer paradigm. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.